PT3733712T - Regimes e métodos de tratamento de esclerose múltipla que usam ofatumumab - Google Patents
Regimes e métodos de tratamento de esclerose múltipla que usam ofatumumabInfo
- Publication number
- PT3733712T PT3733712T PT201809381T PT20180938T PT3733712T PT 3733712 T PT3733712 T PT 3733712T PT 201809381 T PT201809381 T PT 201809381T PT 20180938 T PT20180938 T PT 20180938T PT 3733712 T PT3733712 T PT 3733712T
- Authority
- PT
- Portugal
- Prior art keywords
- ofatumumab
- methods
- multiple sclerosis
- treatment regimes
- sclerosis treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Meat, Egg Or Seafood Products (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pressure Welding/Diffusion-Bonding (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662374986P | 2016-08-15 | 2016-08-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3733712T true PT3733712T (pt) | 2023-08-31 |
Family
ID=59901554
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT201809381T PT3733712T (pt) | 2016-08-15 | 2017-08-11 | Regimes e métodos de tratamento de esclerose múltipla que usam ofatumumab |
| PT177688637T PT3497132T (pt) | 2016-08-15 | 2017-08-11 | Regimes e métodos de tratamento de esclerose múltipla que usam ofatumumab |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT177688637T PT3497132T (pt) | 2016-08-15 | 2017-08-11 | Regimes e métodos de tratamento de esclerose múltipla que usam ofatumumab |
Country Status (24)
| Country | Link |
|---|---|
| US (5) | US11161909B2 (enExample) |
| EP (4) | EP4371611A3 (enExample) |
| JP (2) | JP6851391B2 (enExample) |
| KR (2) | KR20200136503A (enExample) |
| CN (5) | CN109641965A (enExample) |
| AU (2) | AU2017311664C1 (enExample) |
| CA (2) | CA3030530C (enExample) |
| CY (1) | CY1123350T1 (enExample) |
| DE (1) | DE202017007542U1 (enExample) |
| DK (2) | DK3497132T3 (enExample) |
| ES (2) | ES2954259T3 (enExample) |
| FI (1) | FI3733712T3 (enExample) |
| HR (2) | HRP20201388T1 (enExample) |
| HU (2) | HUE063625T2 (enExample) |
| IL (4) | IL276890B2 (enExample) |
| LT (2) | LT3733712T (enExample) |
| MX (1) | MX388593B (enExample) |
| PL (2) | PL3497132T3 (enExample) |
| PT (2) | PT3733712T (enExample) |
| RS (2) | RS60807B1 (enExample) |
| RU (1) | RU2749951C2 (enExample) |
| SI (2) | SI3733712T1 (enExample) |
| TW (1) | TWI752995B (enExample) |
| WO (1) | WO2018033841A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109641965A (zh) * | 2016-08-15 | 2019-04-16 | 诺华股份有限公司 | 使用奥法木单抗治疗多发性硬化的方案和方法 |
| CN118403156A (zh) | 2019-09-11 | 2024-07-30 | 诺华股份有限公司 | 通过转换疗法治疗rms |
| US20220389109A1 (en) * | 2019-09-11 | 2022-12-08 | Novartis Ag | Management of conditions other than multiple sclerosis in ofatumumab-treated patients |
| IL296701A (en) * | 2020-04-09 | 2022-11-01 | Novartis Ag | Ofatumumab for the treatment of multiple sclerosis while maintaining IgG in the serum |
| WO2022219057A1 (en) * | 2021-04-14 | 2022-10-20 | Novartis Ag | Ofatumumab for treating multiple sclerosis in asian patients |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| US4816401A (en) | 1985-09-09 | 1989-03-28 | University Of Rochester | Serum free cell culture medium |
| WO1987002671A1 (en) | 1985-11-01 | 1987-05-07 | International Genetic Engineering, Inc. | Modular assembly of antibody genes, antibodies prepared thereby and use |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
| AU5108201A (en) | 2000-03-30 | 2001-10-15 | Amgen Inc | Cd20/ige-receptor like molecules and uses thereof |
| CA2634294A1 (en) | 2000-08-03 | 2002-02-14 | Therapeutic Human Polyclonals, Inc. | Production of humanized antibodies in transgenic animals |
| WO2004035607A2 (en) | 2002-10-17 | 2004-04-29 | Genmab A/S | Human monoclonal antibodies against cd20 |
| US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
| DOP2006000029A (es) | 2005-02-07 | 2006-08-15 | Genentech Inc | Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas) |
| US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| UA107557C2 (xx) * | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
| TW201438738A (zh) | 2008-09-16 | 2014-10-16 | Genentech Inc | 治療進展型多發性硬化症之方法 |
| EP2600861A1 (en) | 2010-08-02 | 2013-06-12 | Sanofi-Aventis U.S. LLC | Use of teriflunomide for treating multiple sclerosis |
| JP2014506258A (ja) * | 2011-01-10 | 2014-03-13 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | 新規使用 |
| MX363819B (es) * | 2012-02-08 | 2019-04-03 | Igm Biosciences Inc | Uniones a cdim y sus usos. |
| EP2692343A1 (en) | 2012-08-03 | 2014-02-05 | Forward Pharma A/S | Combination therapy for treatment of multiple sclerosis |
| EP2882741B1 (en) * | 2012-08-10 | 2018-10-24 | Boehringer Ingelheim International GmbH | Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors |
| WO2015162504A1 (en) | 2014-04-23 | 2015-10-29 | Novartis Ag | Novel dosing and uses of ofatumumab |
| UY36099A (es) | 2014-04-29 | 2016-02-29 | Teva Pharma | Laquinimod para el tratamiento de pacientes con esclerosis múltiple remitente recurrente (rrms) con un alto grado de discapacidad |
| EP3250927B1 (en) | 2015-01-28 | 2020-02-19 | H. Hoffnabb-La Roche Ag | Gene expression markers and treatment of multiple sclerosis |
| CN106699886A (zh) | 2015-07-13 | 2017-05-24 | 西藏海思科药业集团股份有限公司 | 抗体依赖性细胞介导的细胞毒性(adcc)增强的奥法木抗体 |
| CN109641965A (zh) | 2016-08-15 | 2019-04-16 | 诺华股份有限公司 | 使用奥法木单抗治疗多发性硬化的方案和方法 |
| CN118403156A (zh) | 2019-09-11 | 2024-07-30 | 诺华股份有限公司 | 通过转换疗法治疗rms |
| US20220389109A1 (en) | 2019-09-11 | 2022-12-08 | Novartis Ag | Management of conditions other than multiple sclerosis in ofatumumab-treated patients |
| IL296701A (en) | 2020-04-09 | 2022-11-01 | Novartis Ag | Ofatumumab for the treatment of multiple sclerosis while maintaining IgG in the serum |
| WO2022219057A1 (en) | 2021-04-14 | 2022-10-20 | Novartis Ag | Ofatumumab for treating multiple sclerosis in asian patients |
| US20240343821A1 (en) | 2021-08-16 | 2024-10-17 | Novartis Ag | Ofatumumab for treating pediatric ms |
-
2017
- 2017-08-11 CN CN201780049932.7A patent/CN109641965A/zh active Pending
- 2017-08-11 PL PL17768863T patent/PL3497132T3/pl unknown
- 2017-08-11 IL IL276890A patent/IL276890B2/en unknown
- 2017-08-11 RS RS20201066A patent/RS60807B1/sr unknown
- 2017-08-11 MX MX2019001860A patent/MX388593B/es unknown
- 2017-08-11 FI FIEP20180938.1T patent/FI3733712T3/fi active
- 2017-08-11 DE DE202017007542.3U patent/DE202017007542U1/de active Active
- 2017-08-11 CN CN202510270924.1A patent/CN120000782A/zh active Pending
- 2017-08-11 US US16/324,619 patent/US11161909B2/en active Active
- 2017-08-11 EP EP24166956.3A patent/EP4371611A3/en active Pending
- 2017-08-11 PL PL20180938.1T patent/PL3733712T3/pl unknown
- 2017-08-11 CN CN202510270961.2A patent/CN120053639A/zh active Pending
- 2017-08-11 CN CN202510270941.5A patent/CN120053638A/zh active Pending
- 2017-08-11 KR KR1020207034140A patent/KR20200136503A/ko not_active Ceased
- 2017-08-11 IL IL302488A patent/IL302488B2/en unknown
- 2017-08-11 EP EP17768863.7A patent/EP3497132B1/en active Active
- 2017-08-11 ES ES20180938T patent/ES2954259T3/es active Active
- 2017-08-11 EP EP20180938.1A patent/EP3733712B1/en active Active
- 2017-08-11 ES ES17768863T patent/ES2821924T3/es active Active
- 2017-08-11 RS RS20230635A patent/RS64541B1/sr unknown
- 2017-08-11 DK DK17768863.7T patent/DK3497132T3/da active
- 2017-08-11 KR KR1020197007454A patent/KR20190038914A/ko not_active Ceased
- 2017-08-11 SI SI201731396T patent/SI3733712T1/sl unknown
- 2017-08-11 LT LTEP20180938.1T patent/LT3733712T/lt unknown
- 2017-08-11 PT PT201809381T patent/PT3733712T/pt unknown
- 2017-08-11 LT LTEP17768863.7T patent/LT3497132T/lt unknown
- 2017-08-11 HR HRP20201388TT patent/HRP20201388T1/hr unknown
- 2017-08-11 IL IL313932A patent/IL313932A/en unknown
- 2017-08-11 SI SI201730400T patent/SI3497132T1/sl unknown
- 2017-08-11 PT PT177688637T patent/PT3497132T/pt unknown
- 2017-08-11 HR HRP20230894TT patent/HRP20230894T1/hr unknown
- 2017-08-11 JP JP2018550539A patent/JP6851391B2/ja active Active
- 2017-08-11 DK DK20180938.1T patent/DK3733712T3/da active
- 2017-08-11 AU AU2017311664A patent/AU2017311664C1/en active Active
- 2017-08-11 RU RU2019107146A patent/RU2749951C2/ru active
- 2017-08-11 HU HUE20180938A patent/HUE063625T2/hu unknown
- 2017-08-11 CN CN202510270903.XA patent/CN120037367A/zh active Pending
- 2017-08-11 CA CA3030530A patent/CA3030530C/en active Active
- 2017-08-11 CA CA3101514A patent/CA3101514A1/en active Pending
- 2017-08-11 EP EP23172507.8A patent/EP4252847A3/en active Pending
- 2017-08-11 HU HUE17768863A patent/HUE051948T2/hu unknown
- 2017-08-11 WO PCT/IB2017/054909 patent/WO2018033841A1/en not_active Ceased
- 2017-08-15 TW TW106127565A patent/TWI752995B/zh active
-
2019
- 2019-02-12 IL IL264804A patent/IL264804B/en active IP Right Grant
-
2020
- 2020-02-07 JP JP2020019337A patent/JP7198786B2/ja active Active
- 2020-02-17 AU AU2020201112A patent/AU2020201112C1/en active Active
- 2020-09-11 CY CY20201100861T patent/CY1123350T1/el unknown
-
2021
- 2021-10-06 US US17/495,559 patent/US20220081488A1/en not_active Abandoned
-
2023
- 2023-06-08 US US18/331,701 patent/US20240150485A1/en active Pending
-
2024
- 2024-03-06 US US18/597,624 patent/US12338290B2/en active Active
-
2025
- 2025-05-28 US US19/221,422 patent/US20250289902A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL290994A (en) | Methods of diagnosing and treating conduct disorder | |
| KR102478638B9 (ko) | 진단 방법 및 이를 수행하는 기기 | |
| IL259570A (en) | Combined therapy and their uses and methods | |
| IL257105A (en) | Modified cells and methods of therapy | |
| EP3559784C0 (en) | Haptic interaction method and system | |
| SG11201703193XA (en) | Treatment for depression and depressive disorders | |
| BR112017018413A2 (pt) | tratamento de pancreatite | |
| EP3181744A4 (en) | Treatment device and treatment method | |
| GB2553086B (en) | Decoder devices, methods and computer programs | |
| EP3445431A4 (en) | PATIENT INTERFACE AND ASPECTS THEREOF | |
| PT3733712T (pt) | Regimes e métodos de tratamento de esclerose múltipla que usam ofatumumab | |
| PL3280423T3 (pl) | Kompozycje i sposoby do synergistycznego leczenia glikokaliksu | |
| GB201509404D0 (en) | Ultrasonic pre-cleaning bath and method | |
| EP4057700C0 (en) | MULTI-USER ACCESS METHOD AND APPARATUS | |
| EP3493821A4 (en) | METHOD OF TREATING THE RESPIRATORY TRACT | |
| PL3373922T3 (pl) | Kompozycje i sposoby do stosowania do leczenia homocystynurii | |
| GB2539474B (en) | Glove and treatment method | |
| HRP20210070T8 (hr) | Dijagnostički uređaj i odgovarajuća metoda | |
| EP3307775A4 (en) | Methods for diagnosing and treating affective disorders | |
| GB201603631D0 (en) | Therapy and diagnostics | |
| EP3678672A4 (en) | ALDOXORUBICIN-BASED METHODS AND POLYTHERAPIES | |
| LT3364975T (lt) | Trazodono ir gabapentino derinys, skirtas skausmo gydymui | |
| ZA201802201B (en) | Novel formulation and treatment methods | |
| SI3307267T1 (sl) | Zdravljenje multiple skleroze | |
| LT3268372T (lt) | Kv1.3 inhibitoriai ir jų medicininis taikymas |